• Vaccine Name: Typhim Vi
• Target Pathogen: Salmonella spp.
• Target Disease: Salmonellosis
• Product Name: Typhoid Vi Polysaccharide Vaccine
• Tradename: Typhim Vi
• Manufacturer: Sanofi Pasteur SA
• Vaccine Ontology ID: VO_0000104
• CDC CVX code: 101
• Type: Subunit vaccine
• Status: Licensed
• Location Licensed: USA (License #1724)
• Host Species for Licensed Use: Human
• Antigen: The Vi-antigen is a polysaccharide capsule found only in S. enterica serovars Dublin, Typhi, and Paratyphi C The Vi-antigen is a polysaccharide capsule found only in S. enterica serovars Dublin, Typhi, and Paratyphi C (Cheminay and Hensel, 2007).
• Preservative: Phenol
• Immunization Route: Intramuscular injection (i.m.)
• Storage: Store at 2° to 8°C (35° to 46°F). DO NOT FREEZE.
• Approved Age for Licensed Use: Two years of age and older.
• Contraindication: TYPHIM Vi VACCINE IS CONTRAINDICATED IN PATIENTS WITH A HISTORY OF HYPERSENSITIVITY TO ANY COMPONENT OF THIS VACCINE (Typhim Vi).
• Description: Contains the cell surface Vi polysaccharide extracted from Salmonella enterica serovar Typhi, S typhi Ty2 strain. The organism is grown in a semi-synthetic medium without animal proteins. The capsular polysaccharide is precipitated from the concentrated culture supernatant by the addition of hexadecyltrimethylammonium bromide and the product is purified by differential centrifugation and precipitation (Typhim Vi).

Human Response

• Side Effects: The most common side effects reported are: injection site reactions, fever, headache, nausea, and malaise (Typhim Vi).
• Efficacy: The overall protective efficacy of Typhim Vi vaccine was 74% confirmed by a blood culture of confirmed cases of typhoid fever during 20 months of post-vaccination follow-up (Typhim Vi).